Transcatheter Aortic Valve Replacement in a Failed Homograft

Puntos clave

• To explore the effectiveness of transcatheter aortic valve replacement in patients with failed homografts.
• Discussion of TAVR devices designed specifically for aortic regurgitation (AR) treatment.
• Analysis of the implications of commercial approval for TAVR devices.
• TAVR is likely to become the preferred treatment option for patients with failed homografts after commercial approval.